LLY
Eli Lilly and Company
LLY has the edge over RMTI overall, supported by stronger fundamentals and lower modeled downside.
RMTI
Rockwell Medical, Inc.
RMTI's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
RMTI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Stable | |
| Strong |
RMTI's balance sheet is currently strong, and its revenue and cash flow are stable, but its profitability is under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
RMTI PE Valuation
RMTI has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over RMTI on the outlook, with more favorable profitability expectations.
RMTI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Stable | |
| Limited | |
| High |
Analysts expect RMTI's losses to shrink, with revenue growing.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over RMTI on earnings quality, reporting a profit while its opponent remains loss making.
RMTI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.43 | +$0.17 |
| Q2 2026 | -$1.34 | -$0.64 |
| Q1 2026 | -$1.50 | -$1.40 |
| Q4 2025 | -$1.50 | -$1.20 |
| Q3 2025 | -$1.60 | -$1.16 |
| Q2 2025 | -$0.70 | +$0.84 |
| Q1 2025 | -$0.10 | +$3.34 |
| Q4 2024 | -$0.30 | +$3.54 |
RMTI is still losing money, but far less than before: $1.43 per share over the past year, against $61.60 at its worst in late 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over RMTI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over RMTI on profitability, with a higher operating margin.
RMTI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19.1M | +20% |
| Q2 2026 | $17.8M | +11% |
| Q1 2026 | $17.3M | -8.3% |
| Q4 2025 | $18.3M | -26% |
| Q3 2025 | $15.9M | -44% |
| Q2 2025 | $16.1M | -38% |
| Q1 2025 | $18.9M | -17% |
| Q4 2024 | $24.7M | +12% |
RMTI's revenue is recovering but still below its 2024 peak: $19M last quarter, up 20% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -12% | -1.7 points |
| Q2 2026 | -6% | +2.4 points |
| Q1 2026 | -8.5% | -1.3 points |
| Q4 2025 | -2.2% | -0.1 points |
| Q3 2025 | -10% | -17 points |
| Q2 2025 | -8.4% | -10 points |
| Q1 2025 | -7.2% | -1.4 points |
| Q4 2024 | -2.1% | +0.4 points |
RMTI's operating margin was −12% last quarter, down 1.7 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
RMTI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.2M | -$712K |
| Q2 2026 | $1.5M | -13% |
| Q1 2026 | -$592K | +$3M |
| Q4 2025 | $2.2M | +369% |
| Q2 2025 | $1.7M | +17% |
| Q1 2025 | -$3.6M | -$1.2M |
| Q4 2024 | $470K | +$513K |
| Q2 2024 | $1.4M | +$3.2M |
RMTI's free cash flow has turned positive after six years mostly in the red: $828,000 over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over RMTI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
RMTI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +13.4K shares |
| 1 year | +10% | +369K shares |
| 3 years | +115% | +2.1M shares |
| 5 years | +367% | +3.1M shares |
| Available history | +617% | +3.4M shares |
RMTI has 4M diluted shares, up 10% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
RMTI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2025 | -4.3x | Net Cash |
| Q1 2025 | -1.0x | Net Cash |
| Q4 2024 | -2.6x | Net Cash |
| Q3 2024 | -1.4x | Net Cash |
RMTI has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
RMTI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.4 | Neutral |
| Stochastic | 34.5 | Neutral |
RMTI's weekly RSI is 46 (neutral) and its Stochastic is 34 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
RMTI PE vs Healthcare Sector
RMTI has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over RMTI on trend strength, trading above more of its moving averages.
RMTI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.68 | 3.9% below |
| 20 week MA | $7.37 | 0.1% above |
| 50 week MA | $8.25 | 11% below |
| 100 week MA | $10.8 | 32% below |
| 200 week MA | $17.0 | 57% below |
RMTI's trend is mixed: it's above one of its five weekly moving averages, and 57% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over RMTI on returns for 2026, with the stronger performance.
RMTI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $258.5 | $111.1 | -57% |
| 2021 | $111.1 | $44.0 | -60% |
| 2022 | $44.0 | $9.70 | -78% |
| 2023 | $9.70 | $18.9 | +95% |
| 2024 | $18.9 | $21.4 | +13% |
| 2025 | $21.4 | $8.65 | -60% |
| 2026 YTD | $8.65 | $7.38 | -15% |
RMTI has finished lower in four of the last six years. It's down 15% so far in 2026.